Filing Flows › Coherus Oncology (CHRS) › Q3 2026 › vs Q2 2026
Coherus Oncology (CHRS) Q3 2026 vs Q2 2026 (quarter over quarter)
Coherus Oncology's revenue fell $33K (-0.2%) from $14.3M in Q2 2026 to $14.3M in Q3 2026. The biggest changes: Other revenue −$429K (-62%); Toripalimab +$396K (+3%).
Coherus Oncology, Q3 2026: revenue $14.3M (+23% year over year), operating margin -235.7%, net loss $39.3M, operating cash flow −$34.0M. The chart draws each line against Q2 2026, the increases inside each band.
Every line
| Line | Q3 2026 | Q2 2026 | Change | % |
|---|---|---|---|---|
| Toripalimab | $14.0M | $13.6M | $396K | +3% |
| Other revenue | $265K | $694K | −$429K | -62% |
| Revenue | $14.3M | $14.3M | −$33K | -0.2% |
| Net loss | $39.3M | $20.6M | $18.7M | +91% |
| Costs & expenses | $53.6M | $47.7M | $6.0M | +12% |
| Operating costs | $47.9M | $46.6M | $1.3M | +3% |
| Interest & other, net | $5.2M | $1.0M | $4.2M | +414% |
| Income tax | $459K | −$12.7M | $13.2M | — |
| Cost of revenue | $4.1M | $4.2M | −$150K | -4% |
| Research & development | $22.6M | $21.4M | $1.2M | +5% |
| SG&A | $21.2M | $21.0M | $271K | +1% |
| Operating cash sources | $39.3M | $20.6M | $18.7M | +91% |
| Depreciation & amortization | $853K | $862K | −$9K | -1% |
| Share-based compensation | $3.7M | $2.6M | $1.1M | +43% |
| Working capital & other | $780K | −$44.9M | $45.7M | — |
| Cash used in operations | $34.0M | $62.1M | −$28.1M | -45% |
| Net loss absorbed | $39.3M | $20.6M | $18.7M | +91% |
Questions
How much did Coherus Oncology's revenue grow quarter over quarter in Q3 2026?
Coherus Oncology's revenue fell $33K (-0.2%) from $14.3M in Q2 2026 to $14.3M in Q3 2026.
What drove Coherus Oncology's revenue change in Q3 2026?
Other revenue −$429K (-62%); Toripalimab +$396K (+3%).